# Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma

> **NCT00003362** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** QS21
- **BIOLOGICAL:** gp100 antigen
- **BIOLOGICAL:** incomplete Freund's adjuvant
- **BIOLOGICAL:** sargramostim
- **BIOLOGICAL:** tyrosinase peptide

## Key facts

- **NCT ID:** NCT00003362
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-05
- **Primary completion:** 2001-02
- **Final completion:** 2001-02
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003362, "Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00003362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*